Adaptive Biotechnologies Corporation

NASDAQ:ADPT

Biotechnology

Healthcare
$28.46 +3.66%

+$0.61 today

Market cap
$4.61B
Beta
2.15
P/E (TTM)
-54.5
EPS (TTM)
-$0.32
52W Low $9.96High $20.76

Volume 2.21M

Average 1.94M

ADPT Common Stock Issued

Cash raised by issuing new shares.

Adaptive Biotechnologies CorporationNASDAQ: ADPT

Common Stock Issued · Q2 FY2026 · quarter ended Jun 2026

Common stock issued growth accelerates

Q2 FY2026 common stock issued of $5.38M rose 234.3% year over year, ahead of the +227.9% change in trailing-twelve-month common stock issued. Sequentially, it fell 28.2% from the prior quarter. Over 3 fiscal years it compounded at +56.8% a year.

Context

  • Common stock issued amounted to 11.0% of revenue in FY2025, up 10.8 pp from a year earlier.
  • Common stock issued increased in 1 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +234.3% holds above the trailing-twelve-month pace of +227.9%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJun 2026
$5.38M-28.2% QoQ
Last fiscal yearDec 2025
$30.4M+12515.4% YoY
LTMJun 2026
$23.7M+227.9% YoY
Common Stock Issued past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+234.3%——
1 year+12515.4%——
3-year CAGR+56.8%——
5-year CAGR——
10-year CAGR——

Common Stock Issued history

USD · from the cash flow

Latest · FY2025
30.4M USD
Year-over-year change
+12515.4%
4-year CAGR
+3.3%

Common Stock Issued vs competitors

How ADPT compares with its peers on the latest reported figures

  • ADPT's LTM Jun 2026 common stock issued of $23.7M is the 6th largest of the 10 companies compared; the peer median is $77.02M.
  • Its year-over-year change of +227.9% is the highest of 9, against a peer median of -49.3%.
  • Common stock issued amounts to 7.7% of revenue for ADPT, versus a peer median of 9.4%.
ADPT Competitors Peer median
Common Stock Issued for ADPT and competitors
Company Period LTM YoY 3-year CAGR% of revenue
MLYSMineralys Therapeutics, Inc.LTM Jun 2026$556.34M +179.3%——
IRONDisc Medicine, Inc.LTM Sep 2026$216.1M -12.6%+106.8%—
LEGNLegend Biotech CorporationLTM Sep 2026$213.36M —-79.4%15.7%
TARSTarsus Pharmaceuticals, Inc.LTM Sep 2026$115.45M -19.8%+24.2%16.9%
SRRKScholar Rock Holding CorporationLTM Sep 2026$77.02M -77.3%-2.8%13512.8%
ADPTAdaptive Biotechnologies CorporationLTM Jun 2026$23.7M +227.9%+56.8%7.7%
BEAMBeam Therapeutics Inc.LTM Jun 2026$14.62M -96.9%+64.1%9.4%
CPRXCatalyst Pharmaceuticals, Inc.LTM Mar 2026$13.18M -21.4%+15.3%2.2%
IDYAIDEAYA Biosciences, Inc.LTM Mar 2026$4.82M -98.6%-32.1%2.1%
ZLABZai Lab LimitedLTM Jun 2026$2.03M -82.5%—0.5%
Peer median (excluding ADPT) $77.02M-49.3%+15.3%9.4%

Competitors are the stored peer set for ADPT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(207.28M)(200.19M)(225.25M)(159.6M)(59.5M)
Depreciation & Amortization13.95M20.92M22.23M19.26M17.83M
Deferred Income Tax00000
Stock-Based Compensation00053.61M51.48M
Change in Working Capital(56.82M)(71.55M)(46.18M)(17.45M)(57.77M)
Accounts Receivables(7.36M)(22.65M)2.03M(3.74M)(8.65M)
Inventory(5.2M)817K(2.84M)1.94M(998K)
Accounts Payables3.94M7.11M(5.41M)671K665K
Other Working Capital(48.19M)(56.83M)(39.97M)(16.32M)(48.79M)
Other Non-Cash Items57.42M66.87M92.88M8.97M1.96M
Operating Cash Flow(192.73M)(183.95M)(156.32M)(95.21M)(45.99M)
Capital Expenditures(61.75M)(16.35M)(10.7M)(3.66M)(2.96M)
Acquisitions (Net)00000
Purchases of Investments(316.54M)(278.78M)(429.56M)(244.26M)(181.71M)
Sales of Investments559.5M298.03M569.9M325.71M222.62M
Other Investing Activities00000
Investing Cash Flow181.21M2.91M129.65M77.79M37.95M
Debt Repayment0124.38M000
Common Stock Issued26.72M7.89M2.25M241K30.4M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities429K0000
Financing Cash Flow27.15M132.26M2.25M241K30.4M
Effect of Forex Changes0(260K)(534K)00
Net Change in Cash15.63M(49.04M)(24.97M)(17.18M)22.37M
Free Cash Flow(254.47M)(200.29M)(167.02M)(98.88M)(48.95M)

Adaptive Biotechnologies Corporation

NASDAQ:ADPT

Intrinsic Alpha fair value

Locked

Current Price

$28.46

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.